Cohen Capital Management Inc. Buys New Stake in Illumina, Inc. (NASDAQ:ILMN)

Cohen Capital Management Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,742 shares of the life sciences company’s stock, valued at approximately $233,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Empowered Funds LLC boosted its stake in shares of Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares during the last quarter. Bank of Stockton lifted its holdings in Illumina by 3.8% in the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares during the period. Caprock Group LLC boosted its position in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares in the last quarter. Integrated Advisors Network LLC grew its stake in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Finally, Stephens Inc. AR grew its stake in shares of Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after purchasing an additional 90 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Illumina stock opened at $94.20 on Friday. The company has a fifty day simple moving average of $127.98 and a 200-day simple moving average of $134.13. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $14.92 billion, a price-to-earnings ratio of -12.27, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 52-week low of $93.50 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ILMN. Stephens boosted their target price on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Royal Bank of Canada lowered their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group dropped their target price on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, February 7th. Morgan Stanley reduced their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Finally, Piper Sandler raised their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.